

Press release from Emotra AB (publ)

Göteborg, June 15, 2021

Emotra AB's rights issue was heavily over-subscribed, with applications amounting to 176 percent of the issue amount. This new share issue will provide the Company with appr. 9.5 MSEK.

In the fully underwritten rights issue in Emotra AB ("Emotra" or "the Company") amounting to appr. 9.5 MSEK that was announced on April 22, 2021 ("the rights issue"), applications for a total of approximately 176 percent of the issue amount were received. The issue will provide the Company with about 9.5 million SEK before issue expenses.

Subscription

The subscription period ended on June 11, 2021. Subscription applications through unit rights amounted to appr. 82.2 percent, while applications without unit rights amounted to appr. 93.8 percent of the total issue volume. Emotra received applications totalling approximately 16.7 MSEK, or 176% of the maximum issue amount.

Allocation

The allocation of units subscribed without unit right has been carried out in accordance with the conditions for the allocation in the preferential rights issue, which are specified in the memorandum prepared for the rights issue. The affected shareholders will be notified separately through a purchase statement. Shareholders with administered shareholding will be notified of their share allocation in accordance with each respective administrator's instructions.

CEO Daniel Poté has the following to say about the outcome

"I appreciate the strong support shown by our existing shareholders and everyone else who has chosen to purchase shares in this issue. I am grateful for their continued support for Emotra's strategic direction and the work ahead. We will proceed with the projects we have communicated, with a focus on clinical studies, technical development and collaboration for continued development of EDOR."

Shares and equity

This Rights Issue will increase Emotra's equity by 603,680.768 SEK, from 905,521.171 SEK to 1,509,201.939 SEK through the issue of 31,772,672 new shares. The number of subscription warrants in the TO 2 series will amount to 15,886,336, while the number of warrants in the TO 3 series will amount to 15,886,336.

Underwriting

External investors have provided guarantees in connection with this rights issue. For these guarantees, the underwriters will be awarded a commission amounting to 12 percent of the underwriting amount in cash, or 14 percent of the underwriting amount in the form of newly issued shares in the Company. Underwriters who wish to receive their commission in the form of newly issued shares shall notify Mangold Fondkommission no later than June 16, 2021. The subscription price for shares issued as underwriter commission has been set to 0.433 SEK per share, which corresponds to the volume-weighted average share price for shares in the Company in the subscription period of the rights issue. A maximum of 3,081,875 new shares will thereby be issued as underwriter commission to the underwriters.

Advisers



Mangold Fondkommission AB has been our financial adviser and issue institute. The Company's legal adviser in connection with this rights issue is Qap Legal.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB, AstraZeneca BioVentureHub, Pepparedsleden 1
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, www.emotra.se